Prof. Dr. Ulrike Haug

Education and academic positions
  • Since 8/2023 Deputy scientific director at the Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany
  • Since 2015 Professor of Clinical Epidemiology and Pharmacoepidemiology at the University of Bremen and Head of the Department Clinical Epidemiology at BIPS, Bremen
  • 2010-2015 Group Leader, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 03/2013 Habilitation and Venia Legendi for Epidemiology at the Medical Faculty of the Ruprecht-Karls-University of Heidelberg
  • 2008-2009 Visiting Assistant Research Professor, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, USA
  • 2006-2010 Postdoctoral Research Fellow, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 07/2006 PhD in Epidemiology, University of Heidelberg
  • 2002-2005 PhD program in Epidemiology (DFG-funded Graduiertenkolleg 793), German Centre for Research on Ageing, Heidelberg, Germany
  • 01/2003 Approbation as Pharmacist
  • 2001-2002 Working in a pharmacy (Heidelberg) and pharmaceutical industry (Karlsruhe) for accreditation as Pharmacist
  • 1997-2001 Study of Pharmacy at the University of Wurzburg, Germany
Professional activities
  • Since 2020 Selected as a CORE member of the ISPE RWE Task Force: RWE and Oncology Subgroup
  • Since 2019 Elected member of the Scientific Council of the International Agency for Research on Cancer (IARC)
  • Since 2019 Invited member of the expert committee “Cancer Prevention” of the National Decade Against Cancer
  • Since 2018 Head of expert group “Medication and Pharmacoepidemiology” of the German National Cohort (NAKO)
  • Since 2018 Section editor “Pharmacoepidemiology” of the journal Current Epidemiology Reports
  • Since 2018 Invited member and deputy chair of the advisory board of the German Centre for Cancer Registry Data (ZFKD) at the Robert Koch Institute
  • Since 2017 Invited member of the expert advisory board of the foundation “Stiftung LebensBlicke”
  • Since 2016 Invited member of the expert committee “Early cancer detection” of the German Cancer Aid
  • Since 2016 Member of the data and safety monitoring board of the European Polyp Surveillance (EPOS) trials
  • Since 2016 Mentor in mentoring programs of the University of Düsseldorf and the University of Würzburg
  • 2015 Consultant to the Ministry of Health of the Grand Duchy of Luxembourg on the establishment of an organized colon cancer screening program
  • Since 2015 Invited member of the international expert working group “Right-sided lesions and interval colorectal cancer” (World Endoscopy Organization)
  • Since 2012 Invited member of the international expert working group “Development and evaluation of new tests for colorectal cancer screening” (World Endoscopy Organization)
  • Since 2012 Reviewer for national and international funding organizations (e.g. German Research Foundation, The Netherlands Organization for Health Research and Development)

ORCID iD: https://orcid.org/0000-0002-1886-2923

  • Epidemiology of colorectal carcinoma, colorectal cancer screening, cancer prevention in risk groups, pharmacoepidemiology

    Selected BIPS-Publications

  • Articles with peer review

  • Amann U, Wentzell N, Kollhorst B, Haug U. Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study. Reproductive Toxicology. 2023;119:108415.
    https://doi.org/10.1016/j.reprotox.2023.108415
  • Bresalier RS, Senore C, Young GP, Allison J, Benamouzig R, Benton S, Bossuyt PM, Caro L, Carvalho B, Chiu H-M, Coupé VM, de Klaver W, de Klerk CM, Dekker E, Dolwani S, Fraser CG, Grady W, Guittet L, Gupta S, Halloran SP, Haug U, Hoff G, Itzkowitz S, Kortlever T, Koulaouzidis A, Ladabaum U, Lauby-Secretan B, Leja M, Levin B, Levin TR, Macrae F, Meijer GA, Melson J, O'Morain C, Parry S, Rabeneck L, Ransohoff DF, Sáenz R, Saito H, Sanduleanu-Dascalescu S, Schoen RE, Selby K, Singh H, Steele RJ, Sung JJY, Symonds EL, Winawer SJ. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: The guiding principles. Gut. 2023;72(10):1904-1918.
    http://dx.doi.org/10.1136/gutjnl-2023-329701
  • Haug U, Kollhorst B, Schink T, Thöne K, Dathe K, Schaefer C, Onken M. Investigating drug safety in pregnancy based on the German Pharmacoepidemiological Research Database (GePaRD): A proof-of-concept analysis on the association between valproate and spina bifida. Pharmacoepidemiology and Drug Safety. 2023;32(2):148-157.
    https://doi.org/10.1002/pds.5573
  • Heinig M, Schäfer W, Langner I, Zeeb H, Haug U. German mammography screening program: Adherence, characteristics of (non-)participants and utilization of non-screening mammography - A longitudinal analysis. BMC Public Health. 2023;23:1678.
    https://doi.org/10.1186/s12889-023-16589-5
  • Heinze F, Czwikla J, Heinig M, Langner I, Haug U. German mammography screening program: Program sensitivity between 2010 and 2016 estimated based on German health claims data. BMC Cancer. 2023;23:852.
    https://doi.org/10.1186/s12885-023-11378-0
  • Neubert A, Toni I, König J, Malonga Makosi D, Mildenberger P, Romanos M, Bertsche A, Bertsche T, Dahlem P, Egberts K, Erdlenbruch B, Fekete S, Haug U, Horneff G, Hübler A, Kiess W, Neininger MP, Niehues T, Sachs B, Schettler KF, Schreeck F, Steimle T, Wenzl T, Wirth S, Zepp F, Schwab M, Urschwitz MS, Rascher W, im Namen des KiDSafe Konsortium. A complex intervention to prevent medication-related hospital admissions: Results of the stepped-wedge cluster-randomized trial KiDSafe in pediatrics. Deutsches Ärzteblatt International. 2023;120(25):425-431.
    https://doi.org/10.3238/arztebl.m2023.0123
  • Rach S, Kühne L, Zeeb H, Ahrens W, Haug U, Pohlabeln H. Mild COVID-19 infection associated with post-COVID-19 condition after 3 months – A questionnaire survey. Annals of Medicine. 2023;55(1):2226907.
    https://doi.org/10.1080/07853890.2023.2226907
  • Reilev M, Jensen PB, Ranch LS, Egenberg A, Furu K, Gembert K, Hägg D, Haug U, Karlstad Ø, Reutfors J, Schäfer W, Schwarz S, Smits E, Holthuis E, Herings R, Trifirò G, Kirchmayer U, Cesare Rosa A, Belleudi V, Gini R, Støvring Henrik, Hallas J. Methodology of the brodalumab assessment of hazards: A multicentre observational safety (BRAHMS) study. BMJ Open. 2023;13:e066057.
    https://doi.org/10.1136/bmjopen-2022-066057
  • Reinold J, Kollhorst B, Temme HL, Wentzell N, Haug U. Use of acitretin among girls and women of childbearing age and occurrence of acitretin-exposed pregnancies in Germany. Clinical Drug Investigation. 2023;43(11):865-872.
    https://doi.org/10.1007/s40261-023-01314-2
  • Riedel O, Viebrock J, Haug U. Overall survival in 92,991 colorectal cancer patients in Germany: Differences according to type of comorbidity. Acta Oncologica. 2023;62(12):1931-1938.
    https://doi.org/10.1080/0284186X.2023.2282120
  • Schwarz S, Hornschuch M, Pox C, Haug U. Colorectal cancer after screening colonoscopy: 10-year incidence by site and detection rate at first repeat colonoscopy. Clinical and Translational Gastroenterology. 2023;14(1):e00535.
    https://doi.org/10.14309/ctg.0000000000000535
  • Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. International Journal of Cancer. 2023;152(8):1547-1555.
    https://doi.org/10.1002/ijc.34375
  • Voss A, Kollhorst B, Platzbecker K, Amann U, Haug U. Risk profiles of new users of oral anticoagulants between 2011 and 2019 in Germany. Clinical Epidemiology. 2023;15:827-837.
    https://doi.org/10.2147/CLEP.S405585
  • Voss A, Smits E, Swart KM, Balabanova Y, Brobert G, Suzart-Woischnik K, Herings R, Schink T, Haug U. Time trends in patient characteristics of new rivaroxaban users with atrial fibrillation in Germany and the Netherlands. Drugs - Real World Outcomes. 2023;10(2):215-224.
    https://doi.org/10.1007/s40801-022-00350-2
  • Wentzell N, Kollhorst B, Reinold J, Haug U. Use of methotrexate in girls and women of childbearing age, occurrence of methotrexate-exposed pregnancies and their outcomes in Germany: A claims data analysis. Clinical Drug Investigation. 2023;43(2):109-117.
    https://doi.org/10.1007/s40261-022-01227-6
  • Willame C, Dodd C, Duran C, Elbers R, Gini R, Bartolini C, Paoletti O, Wang L, Ehrenstein V, Kahlert J, Haug U, Schink T, Diez-Domingo J, Mira-Iglesias A, Carreras JJ, Vergara-Hernández C, Giaquinto C, Barbieri E, Stona L, Huerta C, Martin-Perez M, Garcia-Poza P, de Burgos A, Martinez-Gonzalez M, Bryant V, Villalobos F, Pallejà-Millán M, Aragon M, Carreras JJ, Souverein P, Thurin N, Weibel D, Klungel O, Sturkenboom MCJM. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - An ACCESS cohort study. Vaccine. 2023;41(1):251-262.
    https://doi.org/10.1016/j.vaccine.2022.11.031
  • Asendorf M, Reinold J, Schink T, Kollhorst B, Haug U. Abbildbarkeit des sozioökonomischen Status in der pharmakoepidemiologischen Forschungsdatenbank GePaRD: Beschreibung und Anwendung am Beispiel des Zusammenhangs mit Adipositas. GMS Medizinische Informatik, Biometrie und Epidemiologie. 2022;18(1):Doc02.
    https://doi.org/10.3205/mibe000235
  • Braitmaier M, Kollhorst B, Heinig M, Langner I, Czwikla J, Heinze F, Buschmann L, Minnerup H, García-Albéniz X, Hense H-W, Karch A, Zeeb H, Haug U, Didelez V. Effectiveness of mammography screening on breast cancer mortality - A study protocol for emulation of target trials using German health claims data. Clinical Epidemiology. 2022;14:1293-1303.
    https://doi.org/10.2147/CLEP.S376107
  • Braitmaier M, Schwarz S, Kollhorst B, Senore C, Didelez V, Haug U. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: A prospective study among 55-69-year-olds. Journal of Clinical Epidemiology. 2022;149:118-126.
    https://doi.org/10.1016/j.jclinepi.2022.05.024
  • Dengler R, Straub N, Bredow L, Becker J, Hornschuch M, Riedel O, Haug U, Waldeyer K, Hermes-Moll K, Osburg S, Martin J, Walawgo T, Heidt V, Froschauer S. Ambulante spezialfachärztliche Versorgung (ASV): Eine multiperspektivische Studie zu Status quo, Herausforderungen und Perspektiven. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2022;174:70-81.
    https://doi.org/10.1016/j.zefq.2022.06.003
  • Heinig M, Heinze F, Schwarz S, Haug U. Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery - An analysis of German claims data. BMC Cancer. 2022;22:130.
    https://doi.org/10.1186/s12885-022-09240-w
  • Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. European Journal of Cancer Prevention. 2022;31(6):497-504.
    https://doi.org/10.1097/CEJ.0000000000000736
  • Lansdorp-Vogelaar I, Meester R, de Jonge L, Buron A, Haug U, Senore C. Risk-stratified strategies in population screening for colorectal cancer. International Journal of Cancer. 2022;150(3):397-405.
    https://doi.org/10.1002/ijc.33784
  • Peters A, on behalf of the GNC consortium, Greiser KH, Göttlicher S, Ahrens W, Albrecht M, Bamberg F, Bäringhausen T, Becher H, Berger K, Beule A, Boeing H, Bohn B, Bohnert K, Braun B, Brenner H, Bülow R, Castell S, Damms-Machado A, Dörr M, Ebert N, Ecker M, Emmel C, Fischer B, Franzke C-W, Gastell S, Giani G, Günther M, Günther K, Günther K-P, Haerting J, Haug U, Heid I, Heier M, Heinemeyer D, Hendel T, Herbolsheimer F, Hirsch J, Hoffmann W, Holleczek B, Hölling H, Hörlein A, Jöckel K-H, Kaaks R, Karch A, Karrasch S, Kartschmit N, Kauczor H-U, Keil T, Kemmling Y, Klee B, Klüppelholz B, Kluttig A, Kofink L, Köttgen A, Kraft D, Krause G, Kretz L, Krist L, Kühnisch J, Kuß O, Legath N, Lehnich A-T, Leitzmann M, Lieb W, Linseisen J, Löffler M, Macdonald A, Maier-Hein K, Mangold N, Meinke-Franze C, Meisinger C, Melzer J, Mergarten B, Michels K, Mikolajczyk R, Moebus S, Mueller U, Nauck M, Niendorf T, Nikolaou K, Obi N, Ostrzinski S, Panreck L, Pigeot I, Pischon T, Pschibul-Thamm I, Rathmann W, Reineke A, Roloff S, Rujescu D, Rupf S, Sander O, Schikowski T, Schipf S, Schirmacher P, Schlett CL, Schmidt B, Schmidt G, Schmidt M, Schöne G, Schulz H, Schulze MB, Schweig A, Sedlmeier AM, Selder S, Six-Merker J, Sowade R, Stang A, Stegle O, Steindorf K, Stübs G, Swart E, Teismann H, Thiele I, Thierry S, Ueffing M, Völzke H, Waniek S, Weber A, Werner N, Wichmann H-E, Willich SN, Wirkner K, Wolf K, Wolff R, Zeeb H, Zinkhan M, Zschocke J. Framework and baseline examination of the German National Cohort (NAKO). European Journal of Epidemiology. 2022;37(10):1107-1124.
    https://doi.org/10.1007/s10654-022-00890-5
  • Platzbecker K, Schäfer W, Haug U. Does the socioeconomic status differ between users of potentially NDMA-contaminated generic valsartan and users of brand-name valsartan in Germany? GMS Medizinische Informatik, Biometrie und Epidemiologie. 2022;18(1):Doc3.
    https://doi.org/10.3205/mibe000236
  • Platzbecker K, Wentzell N, Kollhorst B, Haug U. Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: Description of drug utilization and exposed pregnancies in Germany. Multiple Sclerosis and Related Disorders. 2022;67:104184.
    https://doi.org/10.1016/j.msard.2022.104184
    https://repository.publisso.de/resource/frl:6435355
  • Reinold J, Braitmaier M, Riedel O, Haug U. Potential of health insurance claims data to predict fractures in older adults: A prospective cohort study. Clinical Epidemiology. 2022;14:1111-1122.
    https://doi.org/10.2147/CLEP.S379002
  • Schink T, Princk C, Braitmaier M, Haug U. Use of combined oral contraceptives and risk of venous thromboembolism in young women: A nested case-control analysis using German claims data. BJOG: An International Journal of Obstetrics & Gynaecology. 2022;129(13):2107-2116.
    https://doi.org/10.1111/1471-0528.17268
  • Scholle O, Asendorf M, Buck C, Grill S, Jones C, Kollhorst B, Riedel O, Schüz B, Haug U. Regional variations in outpatient antibiotic prescribing in Germany: A small area analysis based on claims data. Antibiotics. 2022;11(7):836.
    https://doi.org/10.3390/antibiotics11070836
  • Thiyagarajan A, Platzbecker K, Ittermann T, Völzke H, Haug U. Estimating incidence and case fatality of thyroid storm in Germany between 2007 and 2017: A claims data analysis. Thyroid. 2022;32(11):1307-1315.
    https://doi.org/10.1089/thy.2022.0096
    https://repository.publisso.de/resource/frl%3A6435247
  • Wentzell N, Haug U. Characterization of pregnancies among women with epilepsy using valproate before or during pregnancy - A longitudinal claims data analysis from Germany. Epilepsy Research. 2022;179:106838.
    https://doi.org/10.1016/j.eplepsyres.2021.106838
    https://repository.publisso.de/resource/frl:6431122
  • Boakye D, Günther K, Niedermaier T, Haug U, Ahrens W, Nagrani R. Associations between comorbidities and advanced stage diagnosis of lung, breast, colorectal, and prostate cancer: A systematic review and meta-analysis. Cancer Epidemiology. 2021;75:102054.
    https://doi.org/10.1016/j.canep.2021.102054
    https://repository.publisso.de/resource/frl%3A6430337
  • Boakye D, Nagrani R, Ahrens W, Haug U, Günther K. The association of comorbidities with administration of adjuvant chemotherapy in stage III colon cancer patients: A systematic review and meta-analysis. Therapeutic Advances in Medical Oncology. 2021;13:1758835920986520.
    https://doi.org/10.1177/1758835920986520
  • Börnhorst C, Reinders T, Rathmann W, Bongaerts B, Haug U, Didelez V, Kollhorst B. Avoiding time-related biases: A feasibility study on antidiabetic drugs and pancreatic cancer applying the parametric g-formula to a large German healthcare database. Clinical Epidemiology. 2021;(13):1027-1038.
    https://doi.org/10.2147/CLEP.S328342
  • Heinig M, Braitmaier M, Haug U. Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016. Pharmacoepidemiology and Drug Safety. 2021;30(4):462-471.
    https://doi.org/10.1002/pds.5186
  • Heinig M, Schwarz S, Haug U. Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. Cancer Epidemiology. 2021;71(Part A):101812.
    https://doi.org/10.1016/j.canep.2020.101812
    https://repository.publisso.de/resource/frl:6425860
  • Komen J, Pottegård A, Mantel-Teeuwisse A, Forslund T, Hjemdahl P, Wettermark B, Hellfritzsch M, Hallas J, Olesen M, Bennie M, Mueller T, Voss A, Schink T, Haug U, Kollhorst B, Karlstad Ø, Kjerpeseth LJ, Klungel O. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021;23(11):1722-1730.
    https://doi.org/10.1093/europace/euab091
  • Marron M, Brackmann K, Kuhse P, Christianson L, Langner I, Haug U, Ahrens W. Vaccination and the risk of childhood cancer - A systematic review and meta-analysis. Frontiers in Oncology. 2021;10:610843.
    https://doi.org/10.3389/fonc.2020.610843
  • Oppelt KA, Kuiper JG, Ingrasciotta Y, Ientile V, Herings R, Tari M, Trifirò G, Haug U. Characteristics and absolute survival of metastatic colorectal cancer patients treated with biologics: A real-world data analysis from three European countries. Frontiers in Oncology. 2021;11:630456.
    https://doi.org/10.3389/fonc.2021.630456
  • Reinold J, Braitmaier M, Riedel O, Haug U. Anticholinergic burden: First comprehensive analysis using claims data shows large variation by age and sex. PLOS ONE. 2021;16(6):e0253336.
    https://doi.org/10.1371/journal.pone.0253336
  • Schäfer W, Reinders T, Riedel O, Haug U. How often are antidepressants prescribed off-label among older adults in Germany? A claims data analysis. British Journal of Clinical Pharmacology. 2021;87(4):1778-1789.
    https://doi.org/10.1111/bcp.14564
  • Schäfer W, Wentzell N, Schink T, Haug U. Characterization of pregnancies exposed to St. John's wort and their outcomes: A claims data analysis. Reproductive Toxicology. 2021;102:90-97.
    https://doi.org/10.1016/j.reprotox.2021.04.005
    https://repository.publisso.de/resource/frl%3A6428346
  • Scholle O, Neubert A, Riedel O, Toni I, Haug U. Repeated use of prescription drugs in pediatrics: Comprehensive overview based on German claims data. Frontiers in Pharmacology. 2021;12:706682.
    https://doi.org/10.3389/fphar.2021.706682
  • Schwarz S, Oppelt KA, Heinig M, Haug U. Potential of German claims data to characterize utilization of new cancer drugs: The example of crizotinib. Future Oncology. 2021;17(18):2305-2313.
    https://doi.org/10.2217/fon-2020-1052
    https://repository.publisso.de/resource/frl:6428548
  • Schwarz S, Schäfer W, Horenkamp-Sonntag D, Liebentraut J, Haug U. Follow-up of 3 million persons undergoing colonoscopy in Germany: Utilization of repeat colonoscopies and polypectomies within 10 years. Clinical and Translational Gastroenterology. 2021;12(1):e00279.
    https://doi.org/10.14309/ctg.0000000000000279
  • Zeeb H, Ahrens W, Haug U, Grabenhenrich L, Pigeot I. Epidemiologische Ansätze zur Klärung wichtiger Forschungsfragen zu COVID-19 - Eine Übersicht. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2021;64(9):1076-1083.
    https://doi.org/10.1007/s00103-021-03378-x
  • Beyerle J, Holowatyj AN, Haffa M, Frei E, Gigic B, Schrotz-King P, Böhm J, Habermann N, Stiborova M, Scherer D, Koelsch T, Skender S, Becker N, Herpel E, Schneider M, Ulrich A, Schirmacher P, Chang-Claude J, Brenner H, Hoffmeister M, Haug U, Owen RW, Ulrich CM. Expression patterns of xenobiotic-metabolizing enzymes in tumor and adjacent normal mucosa tissues among patients with colorectal cancer: The ColoCare Study. Cancer Epidemiology, Biomarkers & Prevention. 2020;29(2):460-469.
    https://doi.org/10.1158/1055-9965.EPI-19-0449
  • Haug U, Coupé VMH. The cumulative false-positive rate in colorectal cancer screening: A Markov analysis. European Journal of Gastroenterology and Hepatology. 2020;32(5):575-580.
    https://doi.org/10.1097/MEG.0000000000001669
  • Krueger K, Jobski K, Voss A, Haug U. Different risk profiles of European patients using direct oral anticoagulants or vitamin K antagonists: A rapid review. Current Epidemiology Reports. 2020;7(4):290-299.
    https://doi.org/10.1007/s40471-020-00257-y
  • Langner I, Riedel O, Czwikla J, Heinze F, Rothgang H, Zeeb H, Haug U. Linkage of routine data to other data sources in Germany: A practical example illustrating challenges and solutions. Das Gesundheitswesen. 2020;82(Suppl. 2):S117-S121.
    https://doi.org/10.1055/a-0999-5509
  • Pisa F, Reinold J, Kollhorst B, Haug U, Schink T. Individual antidepressants and the risk of fractures in older adults: A new user active comparator study. Clinical Epidemiology. 2020;12:667-678.
    https://doi.org/10.2147/CLEP.S222888
  • Schink T, Wentzell N, Dathe K, Onken M, Haug U. Estimating the beginning of pregnancy in German claims data: Development of an algorithm with a focus on the expected delivery date. Frontiers in Public Health. 2020;8:350.
    https://doi.org/10.3389/fpubh.2020.00350
  • Scholle O, Kollhorst B, Haug U. Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. Journal of Internal Medicine. 2020;287(2):171-179.
    https://doi.org/10.1111/joim.12990
  • Buskermolen M, Cenin DR, Helsingen LM, Guyatt G, Vandvik PO, Haug U, Bretthauer M, Lansdorp-Vogelaar I. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: A microsimulation modelling study. The BMJ. 2019;367:l5383.
    https://doi.org/10.1136/bmj.l5383
  • Langner I, Haug U, Scholle O, Lindemann C, Schröder C, Riedel O. Potential explanations for increasing methylphenidate use in children and adolescents with attention-deficit/hyperactivity disorder in Germany from 2004 to 2013. Journal of Clinical Psychopharmacology. 2019;39(1):39-45.
    https://doi.org/10.1097/JCP.0000000000000980
    https://repository.publisso.de/resource/frl%3A6423245
  • Langner I, Ohlmeier C, Haug U, Hense H-W, Czwikla J, Zeeb H. Implementation of an algorithm for the identification of breast cancer deaths in German health insurance claims data: A validation study based on a record linkage with administrative mortality data. BMJ Open. 2019;9:e026834.
    https://doi.org/10.1136/bmjopen-2018-026834
  • Langner I, Ohlmeier C, Zeeb H, Haug U, Riedel O. Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): A validation study using a record linkage with a large cancer registry. BMJ Open. 2019;9:e028223.
    https://doi.org/10.1136/bmjopen-2018-028223
  • Oppelt KA, Luttmann S, Kraywinkel K, Haug U. Incidence of advanced colorectal cancer in Germany: Comparing claims data and cancer registry data. BMC Medical Research Methodology. 2019;19:142.
    https://doi.org/10.1186/s12874-019-0784-y
  • Overbeek J, Kuiper J, van der Heijden A, Labots M, Haug U, Herings R, Nijpels G. Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes. International Journal of Colorectal Disease. 2019;34(2):269-276.
    https://doi.org/10.1007/s00384-018-3191-7
  • Pisa F, Reinold J, Kollhorst B, Haug U, Schink T. Antidepressants and the risk of traumatic brain injury in the elderly: Differences between individual agents. Clinical Epidemiology. 2019;11:185-196.
    https://doi.org/10.2147/CLEP.S173667
  • Bauer A, Riemann JF, Seufferlein T, Reinshagen M, Hollerbach S, Haug U, Unverzagt S, Boese S, Ritter-Herschbach M, Jahn P, Frese T, Harris M, Landenberger M. Invitation to screening colonoscopy in the population at familial risk for colorectal cancer: A cluster-randomized study aimed at increasing participation rates. Deutsches Ärzteblatt International. 2018;115(43):715-722.
    https://doi.org/10.3238/arztebl.2018.0715
  • Czwikla J, Giersiepen K, Langner I, Enders D, Heinze F, Rothgang H, Haug U, Zeeb H, Hense H-W. A cohort study of mammography screening finds that comorbidity measures are insufficient for controlling selection bias. Journal of Clinical Epidemiology. 2018;104:1-7.
    https://doi.org/10.1016/j.jclinepi.2018.07.014
  • Haug U. Aktueller Stand der Evidenz und Entwicklung der Darmkrebsfrüherkennung in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1513-1516.
    https://doi.org/10.1007/s00103-018-2832-x
  • Haug U, Langner I, Zeeb H. Evaluation von organisierten Programmen zur Krebsfrüherkennung: Allgemeine Aspekte und aktueller Stand in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1500-1504.
    https://doi.org/10.1007/s00103-018-2831-y
  • Haug U, Riedel O, Cholmakow-Bodechtel C, Olsson L. First-degree relatives of cancer patients: A target group for primary prevention? A cross-sectional study. British Journal of Cancer. 2018;118(9):1255-1261.
    https://doi.org/10.1038/s41416-018-0057-2
  • Oppelt KA, Haug U. Schmerztherapie bei Darmkrebspatienten - Längsschnittanalysen auf Versichertendaten basierend. Der Onkologe. 2018;24(11):848-860.
    https://doi.org/10.1007/s00761-018-0468-y
    https://repository.publisso.de/resource/frl%3A6417337
  • Plath J, Siebenhofer A, Haug U, Koné I, Hechtner M, Blumenstein I, Schulz-Rothe S, Gerlach FM, Guethlin C. Utilization of colonoscopy and colonoscopic findings among individuals aged 40-54 years with a positive family history of colorectal cancer: A cross-sectional study in general practice. European Journal of Cancer Prevention. 2018;27(6):539-545.
    https://doi.org/10.1097/CEJ.0000000000000399
  • Rutter MD, Beintaris I, Valori R, Chiu HM, Corley D, Dekker E, Forsberg A, Freixas MC, Gore-Booth J, Haug U, Kaminski MF, Matsuda T, Meijer GA, Morris E, Plumb A, Rabeneck L, Robertson D, Schoen R, Singh H, Tinmouth J, Young G, Sanduleanu S. World Endoscopy Organization consensus statements on post-colonoscopy and post-imaging colorectal cancer. Gastroenterology. 2018;155(3):909-925.e3.
    https://doi.org/10.1053/j.gastro.2018.05.038
    https://eprints.whiterose.ac.uk/131233/
  • Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, Onken M, Schaefer C, Dathe K. Valproatverordnungen bei Mädchen und Frauen im gebärfähigen Alter in Deutschland: Untersuchung zeitlicher Trends basierend auf Versichertendaten. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(8):1022-1029.
    https://doi.org/10.1007/s00103-018-2768-1
  • Wentzell N, Schink T, Haug U, Ulrich S, Niemeyer M, Mikolajczyk R. Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. Pharmacoepidemiology and Drug Safety. 2018;27(9):1005-1010.
    https://doi.org/10.1002/pds.4588
    https://repository.publisso.de/resource/frl%3A6417552
  • Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MCW, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: Can the screening interval be extended? Gut. 2017;66(7):1262-1267.
    https://doi.org/10.1136/gutjnl-2015-310102
  • Zia Shams A, Haug U. Strategies for prevention of gastrointestinal cancers in developing countries: A systematic review. Journal of Global Health. 2017;7(2):020405.
    https://doi.org/10.7189/jogh.07.020405
  • Fiederling J, Zia Shams A, Haug U. Validity of self-reported family history of cancer: A systematic literature review on selected cancers. International Journal of Cancer. 2016;139(7):1449-1460.
    https://doi.org/10.1002/ijc.30203
  • Haug U, Becker N. Immunologische Stuhlbluttests zur Darmkrebsfrüherkennung: Schnelltests sind keine vertretbare Option für ein qualitätsgesichertes Programm. Deutsche Medizinische Wochenschrift. 2016;141(10):729-731.
    https://doi.org/10.1055/s-0042-104048
  • Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt P, De Silva M, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJC, Sung JJY, Winawer SJ. Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer. 2016;122(6):826-839.
    https://doi.org/10.1002/cncr.29865

  • Commentaries

  • Haug U, Senore C, Corley D. Promises and potential pitfalls of shared decision-making in cancer screening. Gastroenterology. 2020;158(4):802-805.
    https://doi.org/10.1053/j.gastro.2019.11.293
  • Senore C, Haug U. Faecal immunochemical tests have the potential for correctly ruling out colorectal cancer in symptomatic patients. BMJ Evidence-Based Medicine. 2018;23(3):113-114.
    https://doi.org/10.1136/bmjebm-2018-110901

  • Editorials

  • Haug U, Pigeot I. Krebsfrüherkennung: Ja oder Nein? Facetten einer komplexen Antwort. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1481-1483.
    https://doi.org/10.1007/s00103-018-2844-6
  • Haug U. Flexible sigmoidoscopy screening for colorectal cancer. The BMJ. 2017;356:j75.
    https://doi.org/10.1136/bmj.j75

  • Position papers

  • Deutsche Gesellschaft für Epidemiologie (DGEpi), in collaboration with Haug U, Hense H-W, Twardella D. Stellungnahme zum Beschlussentwurf des G-BA: Richtlinie für organisierte Krebsfrüherkennungsprogramme und Änderung der Krebsfrüherkennungs-Richtlinie. 2018.

  • Editorships

  • Pigeot I, Haug U. Stand der Krebsfrüherkennung in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 61(12). Springer. 2018.

  • Book chapters

  • Haug U. Screening des kolorektalen Karzinoms. In: Schmoll H-J, editors. Kompendium internistische Onkologie. 5. Auflage. Berlin, Heidelberg: Springer. 2020.
    https://doi.org/10.1007/978-3-662-46764-0_76-1

For further publications please follow this link:

  • Vision Zero Präventionsaward 2020
    Netzwerk gegen Krebs (2020)
    Besondere Verdienste zum Thema Prävention und Früherkennung von Darmkrebs
  • Mitglied von / Member of
    AcademiaNet – Expert Database of Outstanding Women in Science (2017)
  • Darmkrebs-Präventionspreis 2016 / Colorectal Cancer Prevention Award 2016
    Deutsche Krebsgesellschaft, Stiftung LebensBlicke und Deutsche Krebsstiftung (2016)
    Darmkrebsvorsorge und -früherkennung
  • Reisestipendium (travel grant) “Best submitted abstracts” / Oral Free Paper Prize
    United European Gastroenterology Week (2014)
  • Felix-Burda-Award for Medical Prevention
    Felix Burda Stiftung (2009)
    Förderung der Darmkrebsprävention und -früherkennung in Deutschland
  • Young Scientist Award (1st prize) of the German Epidemiological Association
    Deutsche Gesellschaft für Epidemiologie (2005)
  • Promotionsstipendium 2002-2005 / PhD scholarship
    Deutsche Forschungsgemeinschaft (2002)

  • Master in Epidemiology at the University of Bremen
  • Bachelor in Public Health at the University of Bremen

The responsibility for the content of this page lies with Ulrike Haug.

Ulrike Haug

Contact

Phone:
+49 (0)421 218-56-862
e-mail:
haug(at)leibniz-bips.de